Skip to main content

Table 1 In vitro activity of 7 aminoglycosides against 300 carbapenem-non susceptible K. pneumoniae in regards to carbapenemase production

From: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance

Antimicrobial agent MIC (mg/L) Clinical breakpoint (mg/L) % Susceptible
Range MIC50 MIC90 EUCAST CLSI EUCAST CLSI
All (n = 300)
 Plazomicin 0.125 - > 256 0.5 4 N/A N/A 87.00% a
 Amikacin 1- > 256 32 128 ≤8 ≤16 18.00% 31.33%
 Gentamicin 0.25- > 256 4 > 256 ≤2 ≤4 43.00% 61.33%
 Tobramycin 0.25- > 256 32 256 ≤2 ≤4 8.67% 11.00%
 Netilmicin 0.25- > 256 128 > 256 ≤2 ≤8 9.00% 13.00%
 Neomycin 0.25- > 256 16 > 256 ≤8b N/A 43.67% a N/A
 Apramycin 1-128 8 16 ≤8c N/A 86.67% c
KPC (n = 201)d
 Plazomicin 0.125 - > 256 1 4 N/A N/A 84.58% a
 Amikacin 1- > 256 32 128 ≤8 ≤16 17.91% 31.34%
 Gentamicin 0.25- > 256 4 64 ≤2 ≤4 48.76% 71.14%
 Tobramycin 0.25- > 256 32 256 ≤2 ≤4 11.94% 14.93%
 Netilmicin 0.25- > 256 128 > 256 ≤2 ≤8 11.94% 16.92%
 Neomycin 0.5- > 256 32 > 256 ≤8b N/A 31.34% b N/A
 Apramycin 1-128 4 16 ≤8c N/A 86.57% c
NDM (n = 52)e
 Plazomicin 0.125 - 2 0.5 1 N/A N/A 100.00% a
 Amikacin 8-256 32 64 ≤8 ≤16 17.31% 44.23%
 Gentamicin 1- > 256 64 > 256 ≤2 ≤4 28.85% 36.54%
 Tobramycin 16- > 256 32 128 ≤2 ≤4 0.00% 0.00%
 Netilmicin 8- > 256 128 > 256 ≤2 ≤8 0.00% 1.92%
 Neomycin 1-32 2 8 ≤8b N/A 94.23% b N/A
 Apramycin 2-32 4 8 ≤8c N/A 94.23% c
VIM (n = 21)
 Plazomicin 0.125 - > 256 1 > 256 N/A N/A 71.43% a
 Amikacin 1- > 256 32 > 256 ≤8 ≤16 19.05% 42.86%
 Gentamicin 1- > 256 128 > 256 ≤2 ≤4 38.10% 42.86%
 Tobramycin 4- > 256 32 > 256 ≤2 ≤4 0.00% 4.76%
 Netilmicin 0.25- > 256 64 > 256 ≤2 ≤8 0.00% 0.00%
 Neomycin 0.5- > 256 32 > 256 ≤8b N/A 33.33% b N/A
 Apramycin 2-64 4 16 ≤8c N/A 80.95% c
OXA-48 (n = 12)
 Plazomicin 0.125 - 4 0.5 2 N/A N/A 91.67% a
 Amikacin 2-64 16 32 ≤8 ≤16 33.33% 58.33%
 Gentamicin 1-256 128 256 ≤2 ≤4 16.67% 16.67%
 Tobramycin 0.5-64 64 64 ≤2 ≤4 16.67% 16.67%
 Netilmicin 0.5-256 128 256 ≤2 ≤8 16.67% 16.67%
 Neomycin 0.25-256 2 16 ≤8b N/A 83.33% b N/A
 Apramycin 4-8 8 8 ≤8c N/A 100.00% c
KPC and VIM (n = 14)
 Plazomicin 0.25 - 2 1 2 N/A N/A 92.86% a
 Amikacin 4- > 256 64 256 ≤8 ≤16 7.14% 28.57%
 Gentamicin 1-64 4 8 ≤2 ≤4 42.86% 78.57%
 Tobramycin 8- > 256 32 128 ≤2 ≤4 0.00% 0.00%
 Netilmicin 4- > 256 128 > 256 ≤2 ≤8 0.00% 7.14%
 Neomycin 0.5- > 256 > 256 > 256 ≤8b N/A 14.29% b N/A
 Apramycin 2-32 8 32 ≤8c N/A 57.14% c
  1. N/A, not available (breakpoints have not been established)
  2. a For plazomicin, the breakpoint recently approved by the FDA was used
  3. b For neomycin, EUCAST epidemiological cut-off values (ECOFFs) for E.coli were used
  4. c For apramycin, epidemiological breakpoints from the European Food Safety Authority (EFSA) were used
  5. d One isolate co-producing KPC and OXA-48-like is included
  6. e Two isolates co-producing NDM and OXA-48-like are included